Susquehanna International Group’s Repros Therapeutics Inc. RPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q4 | – | Sell |
-212,100
| Closed | -$68K | – | 10526 |
|
|
2017
Q3 | $68K | Sell |
212,100
-67,400
| -24% | -$23.6K | ﹤0.01% | 8470 |
|
|
2017
Q2 | $129K | Buy |
279,500
+46,600
| +20% | +$33.9K | ﹤0.01% | 8565 |
|
|
2017
Q1 | $279K | Sell |
232,900
-9,700
| -4% | -$12.1K | ﹤0.01% | 7458 |
|
|
2016
Q4 | $320K | Sell |
242,600
-246,100
| -50% | -$428K | ﹤0.01% | 7851 |
|
|
2016
Q3 | $1.02M | Buy |
488,700
+109,500
| +29% | +$217K | ﹤0.01% | 4762 |
|
|
2016
Q2 | $611K | Buy |
379,200
+198,400
| +110% | +$381K | ﹤0.01% | 5793 |
|
|
2016
Q1 | $175K | Buy |
180,800
+49,500
| +38% | +$48.3K | ﹤0.01% | 8086 |
|
|
2015
Q4 | $159K | Sell |
131,300
-217,300
| -62% | -$697K | ﹤0.01% | 8617 |
|
|
2015
Q3 | $2.59M | Buy |
348,600
+182,300
| +110% | +$1.39M | ﹤0.01% | 3781 |
|
|
2015
Q2 | $1.19M | Sell |
166,300
-141,800
| -46% | -$1.1M | ﹤0.01% | 5828 |
|
|
2015
Q1 | $2.65M | Buy |
308,100
+71,800
| +30% | +$642K | ﹤0.01% | 3769 |
|
|
2014
Q4 | $2.36M | Sell |
236,300
-226,800
| -49% | -$1.93M | ﹤0.01% | 4140 |
|
|
2014
Q3 | $4.58M | Buy |
463,100
+289,500
| +167% | +$4.29M | ﹤0.01% | 3145 |
|
|
2014
Q2 | $3M | Sell |
173,600
-74,200
| -30% | -$1.21M | ﹤0.01% | 3918 |
|
|
2014
Q1 | $4.4M | Sell |
247,800
-21,100
| -8% | -$408K | ﹤0.01% | 3066 |
|
|
2013
Q4 | $4.92M | Sell |
268,900
-191,900
| -42% | -$3.62M | ﹤0.01% | 2966 |
|
|
2013
Q3 | $12.3M | Buy |
460,800
+35,800
| +8% | +$767K | 0.01% | 1672 |
|
|
2013
Q2 | $7.84M | Buy |
+425,000
| New | +$7.51M | ﹤0.01% | 2083 |
|
Susquehanna International Group's RPRX Position: Q1 2018 in Review
Susquehanna International Group sold out of Repros Therapeutics Inc. (RPRX) in Q1 2018, closing a stake of 91,976 shares — an estimated $61K sold.
Susquehanna International Group first reported a position in RPRX in Q2 2013 and held it in 12 quarters. The position peaked at $6.95M in Q3 2013. 1 fund tracked by Wall St. Rank holds RPRX as of Q1 2018.
- Susquehanna International Group reported no remaining Repros Therapeutics Inc. position as of Q1 2018 after selling out during the quarter.
- Susquehanna International Group sold 91,976 Repros Therapeutics Inc. shares in Q1 2018, an estimated $61K.
- Susquehanna International Group first reported a position in Repros Therapeutics Inc. in Q2 2013 and held it in 12 quarters.
- Susquehanna International Group's Repros Therapeutics Inc. position peaked at $6.95M in Q3 2013.
- 1 fund tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q1 2018.
Based on Susquehanna International Group's 13F filing for Q1 2018, filed 15 May 2018.